Find trials
Search tips

Response to PD-1 Blockade in Patients with Mismatch Repair Deficient Colorectal Cancer

Overview

About this study

This study will assess the efficacy and outcomes of PD-1 blockade in patients with mismatch repair deficient colorectal cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. All patients with mismatch repair deficient colorectal cancer receiving pembrolizumab from June 1, 2015 through April 20, 2016 at Mayo Clinic Rochester.

  2. All patients with mismatch repair deficient colorectal cancer receiving pembrolizumab from April 21, 2016 to April 20, 2018.

Exclusion Criteria:

  1. None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Axel Grothey, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20304527

Mayo Clinic Footer